1.
2.
3.
4.
5.
Baker CH, Kedar D, McCarty MF, Tsan R, Weber KL, Bucana CD, Fidler IJ. Blockade of epidermal growth factor receptor signaling on tumor cells and tumor-associated endothelial cells for therapy of human carcinomas . Am J Pathol 161(3):929-38, 2002. PMID: 12213721; PMCID:
PMC1867249.
Bao JJ, Le XF, Wang RY, Yuan J, Wang L, Atkinson EN, LaPushin R, Andreeff M, Fang B, Yu Y, Bast
RC Jr. Reexpression of the tumor suppressor gene ARHI induces apoptosis in ovarian and breast cancer cells through a caspase-independent calpain-dependent pathway . Cancer Res
62(24):7264-72, 2002. PMID: 12499268.
Bast RC Jr, Urban N, Shridhar V, Smith D, Zhang Z, Skates S, Lu K, Liu J, Fishman D, Mills G. Early detection of ovarian cancer: promise and reality . Cancer Treat Res 107:61-97, 2002. PMID:
11775462.
Cooper BC, Ritchie JM, Broghammer CL, Coffin J, Sorosky JI, Buller RE, Hendrix MJ, Sood AK.
Preoperative serum vascular endothelial growth factor levels: significance in ovarian cancer .
Clin Cancer Res 8(10):3193-7, 2002. PMID: 12374688.
Crispens MA, Bodurka D, Deavers M, Lu K, Silva EG, Gershenson DM. Response and survival in patients with progressive or recurrent serous ovarian tumors of low malignant potential . Obstet
Gynecol 99(1):3-10, 2002. PMID: 11777502.
6.
7.
8.
9.
Deavers MT, Gershenson DM, Tortolero-Luna G, Malpica A, Lu KH, Silva EG. Micropapillary and cribriform patterns in ovarian serous tumors of low malignant potential: a study of 99 advanced stage cases . Am J Surg Pathol 26(9):1129-41, 2002. PMID: 12218569.
Deng J, Kloosterbooer F, Xia W, Hung MC. The NH(2)-terminal and conserved region 2 domains of adenovirus E1A mediate two distinct mechanisms of tumor suppression . Cancer Res 62(2):346-
50, 2002. PMID: 11809676.
Fang X, Schummer M, Mao M, Yu S, Tabassam FH, Swaby R, Hasegawa Y, Tanyi JL, LaPushin R,
Eder A, Jaffe R, Erickson J, Mills GB. Lysophosphatidic acid is a bioactive mediator in ovarian cancer . Biochim Biophys Acta 1582(1-3):257-64, 2002. PMID: 12069836.
Fang X, Yu S, Tanyi JL, Lu Y, Woodgett JR, Mills GB. Convergence of multiple signaling cascades at glycogen synthase kinase 3: Edg receptor-mediated phosphorylation and inactivation by lysophosphatidic acid through a protein kinase C-dependent intracellular pathway . Mol Cell Biol
22(7):2099-110, 2002. PMID: 11884598; PMCID: PMC133668.
10. Fidler IJ. Critical determinants of metastasis . Semin Cancer Biol 12(2):89-96, 2002. PMID:
12027580.
11. Fidler IJ. The organ microenvironment and cancer metastasis . Differentiation 70(9-10):498-505,
2002. PMID: 12492492.
12. Gershenson DM. Irinotecan in epithelial ovarian cancer . Oncology (Williston Park) 16(5 Suppl 5):29-
31, 2002. PMID: 12109803.
13. Goodheart MJ, Vasef MA, Sood AK, Davis CS, Buller RE. Ovarian cancer p53 mutation is associated with tumor microvessel density . Gynecol Oncol 86(1):85-90, 2002. PMID: 12079305.
14. Herrera CA, Xu L, Bucana CD, Silva el VG, Hess KR, Gershenson DM, Fidler IJ. Expression of metastasis-related genes in human epithelial ovarian tumors . Int J Oncol 20(1):5-13, 2002. PMID:
11743636.

15. Hu L, Hofmann J, Lu Y, Mills GB, Jaffe RB. Inhibition of phosphatidylinositol 3'-kinase increases efficacy of paclitaxel in in vitro and in vivo ovarian cancer models . Cancer Res 62(4):1087-92,
2002. PMID: 11861387.
16. Hu L, Hofmann J, Zaloudek C, Ferrara N, Hamilton T, Jaffe RB. Vascular endothelial growth factor immunoneutralization plus Paclitaxel markedly reduces tumor burden and ascites in athymic mouse model of ovarian cancer . Am J Pathol 161(5):1917-24, 2002. PMID: 12414537; PMCID:
PMC1850791.
17. Huang S, Van Arsdall M, Tedjarati S, McCarty M, Wu W, Langley R, Fidler IJ. Contributions of stromal metalloproteinase-9 to angiogenesis and growth of human ovarian carcinoma in mice . J
Natl Cancer Inst 94(15):1134-42, 2002. PMID: 12165638.
18. Huang X, Lin T, Gu J, Zhang L, Roth JA, Stephens LC, Yu Y, Liu J, Fang B. Combined TRAIL and
Bax gene therapy prolonged survival in mice with ovarian cancer xenograft . Gene Ther
9(20):1379-86, 2002. PMID: 12365003.
19. Kim JH, Skates SJ, Uede T, Wong KK, Schorge JO, Feltmate CM, Berkowitz RS, Cramer DW, Mok SC.
Osteopontin as a potential diagnostic biomarker for ovarian cancer . Jama 287(13):1671-9, 2002.
PMID: 11926891.
20. Lee WP, Wen Y, Varnum B, Hung MC. Akt is required for Axl-Gas6 signaling to protect cells from
E1A-mediated apoptosis . Oncogene 21(3):329-36, 2002. PMID: 11821945.
21. Lu W, Dong Z, Donawho C, Fidler IJ. Specific immunotherapy against occult cancer metastases .
Int J Cancer 100(4):480-5, 2002. PMID: 12115534.
22. Lutgendorf SK, Johnsen EL, Cooper B, Anderson B, Sorosky JI, Buller RE, Sood AK. Vascular endothelial growth factor and social support in patients with ovarian carcinoma . Cancer
95(4):808-15, 2002. PMID: 12209725.
23. McCarty MF, Baker CH, Bucana CD, Fidler IJ. Quantitative and qualitative in vivo angiogenesis assay . Int J Oncol 21(1):5-10, 2002. PMID: 12063542.
24. Mills GB, Eder A, Fang X, Hasegawa Y, Mao M, Lu Y, Tanyi J, Tabassam FH, Wiener J, Lapushin R,
Yu S, Parrott JA, Compton T, Tribley W, Fishman D, Stack MS, Gaudette D, Jaffe R, Furui T, Aoki J,
Erickson JR. Critical role of lysophospholipids in the pathophysiology, diagnosis, and management of ovarian cancer . Cancer Treat Res 107:259-83, 2002. PMID: 11775454.
25. Modesitt SC, Tortolero-Luna G, Robinson JB, Gershenson DM, Wolf JK. Ovarian and extraovarian endometriosis-associated cancer . Obstet Gynecol 100(4):788-95, 2002. PMID: 12383550.
26. Onn A, Fidler IJ. Metastatic potential of human neoplasms . In Vivo 16(6):423-9, 2002. PMID:
12494885.
27. Petricoin EF, Ardekani AM, Hitt BA, Levine PJ, Fusaro VA, Steinberg SM, Mills GB, Simone C,
Fishman DA, Kohn EC, Liotta LA. Use of proteomic patterns in serum to identify ovarian cancer .
Lancet 359(9306):572-7, 2002. PMID: 11867112.
28. Ramirez PT, Modesitt SC, Morris M, Edwards CL, Bevers MW, Wharton JT, Wolf JK. Functional outcomes and complications of continent urinary diversions in patients with gynecologic malignancies . Gynecol Oncol 85(2):285-91, 2002. PMID: 11972389.
29. Silva EG, Tornos C, Malpica A, Deavers MT, Tortolero-Luna G, Gershenson DM. The association of benign and malignant ovarian adenofibromas with breast cancer and thyroid disorders . Int J
Surg Pathol 10(1):33-9, 2002. PMID: 11927967.

30. Skates SJ. Screening for ovarian cancer-risk, education, worry: path to appropriate use?
Gynecol
Oncol 85(1):1-2, 2002. PMID: 11925112.
31. Sood AK, Coffin J, Jabbari S, Buller RE, Hendrix MJ, Klingelhutz A. p53 null mutations are associated with a telomerase negative phenotype in ovarian carcinoma . Cancer Biol Ther
1(5):511-7, 2002. PMID: 12496479.
32. Sood AK, Fletcher MS, Gruman LM, Coffin JE, Jabbari S, Khalkhali-Ellis Z, Arbour N, Seftor EA,
Hendrix MJ. The paradoxical expression of maspin in ovarian carcinoma . Clin Cancer Res
8(9):2924-32, 2002. PMID: 12231537.
33. Sood AK, Fletcher MS, Zahn CM, Gruman LM, Coffin JE, Seftor EA, Hendrix MJ. The clinical significance of tumor cell-lined vasculature in ovarian carcinoma: implications for antivasculogenic therapy . Cancer Biol Ther 1(6):661-4, 2002. PMID: 12642690.
34. Sun CC, Bodurka DC, Donato ML, Rubenstein EB, Borden CL, Basen-Engquist K, Munsell MF,
Kavanagh JJ, Gershenson DM. Patient preferences regarding side effects of chemotherapy for ovarian cancer: do they change over time?
Gynecol Oncol 87(1):118-28, 2002. PMID: 12468352.
35. Tanyi JL, Lapushin R, Eder A, Auersperg N, Tabassam FH, Roth JA, Gu J, Fang B, Mills GB, Wolf J.
Identification of tissue- and cancer-selective promoters for the introduction of genes into human ovarian cancer cells . Gynecol Oncol 85(3):451-8, 2002. PMID: 12051873.
36. Tedjarati S, Baker CH, Apte S, Huang S, Wolf JK, Killion JJ, Fidler IJ. Synergistic therapy of human ovarian carcinoma implanted orthotopically in nude mice by optimal biological dose of pegylated interferon alpha combined with paclitaxel . Clin Cancer Res 8(7):2413-22, 2002. PMID:
12114447.
37. Ueno NT, Bartholomeusz C, Xia W, Anklesaria P, Bruckheimer EM, Mebel E, Paul R, Li S, Yo GH,
Huang L, Hung MC. Systemic gene therapy in human xenograft tumor models by liposomal delivery of the E1A gene . Cancer Res 62(22):6712-6, 2002. PMID: 12438271.
38. Wolf JK, Jenkins AD. Gene therapy for ovarian cancer (review) . Int J Oncol 21(3):461-8, 2002.
PMID: 12168087.
39. Zhou BP, Hung MC. Novel targets of Akt, p21(Cipl/WAF1), and MDM2 . Semin Oncol 29(3 Suppl
11):62-70, 2002. PMID: 12138399.
40. Zou Y, Peng H, Zhou B, Wen Y, Wang SC, Tsai EM, Hung MC. Systemic tumor suppression by the proapoptotic gene bik . Cancer Res 62(1):8-12, 2002. PMID: 11782349.